Condition
Bacteremia Due to Staphylococcus Aureus
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Terminated1
Withdrawn1
Not Yet Recruiting1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05184764Phase 1Completed
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
NCT07384702Phase 2Not Yet RecruitingPrimary
Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia
NCT05329168Phase 2WithdrawnPrimary
ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis
NCT01975662Phase 2TerminatedPrimary
Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia
Showing all 4 trials